Testing a new digital vaccine platform at a tropical disease hospital
This study tests a prototype digital vaccine platform called TM-VAX with healthcare workers and patients at a hospital for tropical diseases. You can help see if the platform is easy to use and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You are a Thai citizen
- You are either a healthcare worker at the Hospital for Tropical Diseases or a patient there
- You know how to use a computer, mobile phone, and the internet
- You are willing to join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a malaria vaccine (PvRII/Matrix-M) and how well it trains the immune system, then follows safety and effectiveness after a controlled malaria exposure. If you qualify, you’ll be monitored closely in the hospital and receive a curative antimalarial treatment after the exposure.
This study gives healthy volunteers a controlled infection with a type of malaria (vivax) to see how the infection behaves and how well curative anti-malaria medicine works. It may help researchers better design and test future malaria vaccines and treatments.
This trial tests if offering points that can be redeemed for rewards, along with digital tools, can help more people get vaccinated. It uses community support to encourage participation and is open to adults who are able to follow the study requirements.
This study tests whether a digital health tool can help more people start and complete tuberculosis preventive treatment (TPT). If you live with or have close contact with someone who has drug-sensitive TB and live in the area for at least 4 months, you may be able to join.
This study tests an online tool to help people in Southeast Asia feel more confident about vaccines. If you live in Brunei, Indonesia, Malaysia, or Singapore and watch social media in Malay or Indonesian every day, you may be able to join.
This study tests an experimental HIV vaccine that uses tiny particles and mRNA technology in healthy adults. If you qualify, you'll help researchers see if it's safe and if it triggers an immune response.
Hear when a new Evaluate the Prototype Digital Vaccine Platform trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.